Improved cardiometabolic risk in diabetic and non-diabetic overweight/obese patients with rimonabant treatment: data from RIO-Diabetes, RIO-Europe, RIO-North America and RIO-Lipids

被引：0

作者：

Finer, N.

Scheen, A. J.

Despres, J. P.

Pi-Sunyer, F. X.

Van Gaal, L.

机构：

[1] Univ Cambridge, Sch Clin Med, Cambridge, England

[2] Univ Liege, Div Diabet, Liege, Belgium

[3] Laval Hosp, Res Ctr, Quebec Heart Inst, Quebec City, PQ, Canada

[4] St Lukes Roosevelt Hosp, Div Endocrinol, New York, NY 10025 USA

[5] Univ Antwerp Hosp, Dept Diabetol, Antwerp, Belgium

来源：

DIABETIC MEDICINE | 2007年 / 24卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：3 / 4

页数：2

共 18 条

[1] Rimonabant improves multiple cardiometabolic risk factors in diabetic and non-diabetic overweight/obese patients: data from RIO-diabetes, RIO-Europe, RIO-North America and RIO-Lipids
Scheen, A.
Despres, J. -P.
Pi-Sunyer, F. X.
Van Gaal, L.
EUROPEAN HEART JOURNAL, 2006, 27 : 441 - 441
[2] Rimonabant improves glucose tolerance in the overweight or obese non-diabetic patient:: analysis of the RIO-Europe and RIO-Lipids studies
Scheen, A.
Despres, J. P.
Ziegler, O.
Golay, A.
Van Gaal, L.
DIABETES & METABOLISM, 2007, 33 : S68 - S68
[3] The potential of rimonabant in prediabetes: pooled 1-year results from the RIO-Lipids, RIO-Europe and RIO-North America studies
Rosenstock, J
DIABETOLOGIA, 2005, 48 : A16 - A16
[4] Efficacy and safety of rimonabant in the management of cardiovascular risk factors: 2-year pooled data from the RIO-Europe and RIO-North America trials
Van Gaal, L.
Pi-Sunyer, X.
EUROPEAN HEART JOURNAL, 2005, 26 : 642 - 642
[5] Effect of rimonabant on weight reduction, weight maintenance and prevention of weight regain: Design of Rio-North America & Rio-Europe trials
Van Gaal, L
Pi-Sunyer, X
INTERNATIONAL JOURNAL OF OBESITY, 2004, 28 : S160 - S160
[6] Long-term efficacy of rimonabant in improving glucose tolerance in overweight/obese non-diabetic patients: 2-year results from RIO-Europe
Scheen, Andre J.
Van Gaal, Luc
DIABETES, 2008, 57 : A31 - A31
[7] Rimonabant improves glycemic control parameters and glucose tolerance in overweight/obese non diabetic subjects with dyslipidemia.: RIO-Lipids trial
Golay, A
Després, J
Sjöström, L
DIABETOLOGIA, 2004, 47 : A71 - A71
[8] Changes in body composition among dyslipidemic overweight/obese patients treated with rimonabant:: The RIO-lipids trial
Alméras, N
Sjöström, L
Golay, A
Després, JP
OBESITY RESEARCH, 2005, 13 : A193 - A193
[9] Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients - RIO-North America: A randomized controlled trial
Pi-Sunyer, F
Aronne, LJ
Heshmati, HM
Devin, J
Rosenstock, J
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (07): : 761 - 775
[10] Significant improvement in the quality of life of overweight/obese dyslipidemic patients treated with rimonabant:: Results from the RIO-LIPIDS trial
Després, JP
OBESITY RESEARCH, 2004, 12 : A61 - A61

← 1 2 →